A recent meta-analysis confirmed that anti-PD1 and anti-PDL1 immunotherapies are significantly efficacious for patients with advanced, chemotherapy-refractory gastric or GEJ cancer and show even more promising anti-tumor activity and enhanced ORR when tumors overexpress PDL1 [65]. Here, CD274 is linked to neoplasm.